Antares Pharma, Inc. announced that the U.S. Food and Drug Administration has approved TLANDO (testosterone undecanoate), an oral treatment for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. Lipocine licensed the exclusive U.S. commercialization rights for TLANDO to Antares Pharma.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-6.21% | 180B | |
-0.08% | 108B | |
-3.09% | 68.29B | |
-4.84% | 46.96B | |
+12.85% | 45.64B | |
+7.77% | 42.41B | |
+19.71% | 31.01B | |
+16.55% | 25.51B | |
-7.44% | 23.17B |